A Phase 2 interventional study of brentuximab vedotin and brentuximab vedotin in Lymphoma, B-cell and Lymphoma, Large B-cell, Diffuse, sponsored by Seagen Inc.. Terminated at 51 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-21.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse — 4 open to participants now, 8 under way, 1 of them phase 3. Vincristine · Lymphoma, Large B-Cell, Diffuse.
Among the 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse, this one is the 13th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2013, is one of 24 in phase 2, and was the 26th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →4 of the 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse are open now, in 3 countries. Recruiting first, the newest first:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Sites in Russian Federation
Ages 1 days–18 yrs
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
The First Hospital of Jilin University · Sites in China
Ages 18+
By country, each count listing its studies:
Vincristine: first FDA approval 1963 (ONCOVIN). What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 26 · Phase 3 6 · Phase 4 1
First in 1995; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 50 across the 41 interventional studies. Of the 28 that completed or were terminated, 9 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer: none open now, 1 under way, 1 of them phase 3. Of 23 finished, 10 (43%) have results posted.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 9th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 2, and was the 9th registered.
Pfizer’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2006.
2 of the studies testing vincristine in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT04002947National Cancer Institute (NCI)Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | 2027-10-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing vincristine in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Pfizer’s 25 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This study has 3 parts. The purpose of Part 1 of this study is to assess the safety and efficacy of brentuximab vedotin in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (known as BV+RCHOP) in patients with DLBCL who have never been treated. Patients will be randomly assigned in a 1:1 ratio to receive RCHOP together with 1 of 2 doses of brentuximab vedotin. Patients will be tested to see if there is a difference in side effects between the 2 groups.
The purpose of Part 2 of this study is to assess the safety and efficacy of brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) (known as BV+RCHP) in patients with CD30-positive DLBCL who have never been treated. Patients will be enrolled to receive RCHP together with 1.8mg/kg of brentuximab vedotin.
The purpose of Part 3 of this study is to assess the safety and efficacy of BV+RCHP compared to standard RCHOP in patients with CD30-positive DLBCL that have never been treated. Patients will be randomly assigned in a 1:1 ratio to receive either BV+RCHP or RCHOP. Patients will be tested to see if there is a difference in side effects between the 2 groups.
In the first part of this study, patients in the 2 groups were tested to see if there was a difference in the response to treatment and whether there were differences in the side effects (unwanted effects).
The second and third parts of the study are being done to see if there are any side effects (unwanted effects) of the higher dose of brentuximab vedotin when combined with a modified version of RCHOP that omits vincristine. The third part of the study is being done to see if there is a difference between BV+RCHP and RCHOP in the response to treatment.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 87 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP.
Drug: brentuximab vedotin · Drug: rituximab · Drug: vincristine · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin
Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP.
Drug: brentuximab vedotin · Drug: rituximab · Drug: vincristine · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin
Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP.
Drug: brentuximab vedotin · Drug: rituximab · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin
Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone.
Drug: rituximab · Drug: vincristine · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin
Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy. Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP.
Drug: brentuximab vedotin · Drug: rituximab · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin
1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
Also known as: Adcetris, SGN-35
1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
Also known as: Adcetris, SGN-35
375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Complete Remission Rate
Number (count) of participants that achieved remission according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
Time frame: Up to 6 months
Incidence of Adverse Events
Number (count) of participants that experienced at least 1 adverse event.
Time frame: Up to 6 months
Incidence of Laboratory Abnormalities
Number (count) of participants that experienced a Grade 3 or higher maximum post-baseline laboratory toxicity (hematology and chemistry). Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), v4.03. Grade 1 = mild, no intervention needed; Grade 2 = moderate, minimal intervention needed; Grade 3 = severe or medically significant, hospitalization is required; Grade 4 = life-threatening, urgent intervention needed; Grade 5 = death related to adverse event.
Time frame: Up to 6 months
Objective Response Rate
Number (count) of participants that achieved complete or partial remission at the end of treatment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007)
Time frame: Up to 6 months
Progression-free Survival
Median progression-free survival (in months) and observed minimum-maximum range.
Time frame: Up to approximately 4 years
Overall Survival
Median overall survival (in months) and observed minimum-maximum range.
Time frame: Up to approximately 4 years
| Milestone | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Started | 29 | 22 | 11 | 11 | 12 |
| Completed | 25 | 18 | 10 | 10 | 10 |
| Not completed | 4 | 4 | 1 | 1 | 2 |
| Withdrew: Progressive disease | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 3 | 3 | 0 | 1 | 2 |
Number (count) of participants that achieved remission according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
| Participants | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Complete Remission Rate | 20 | 16 | 9 | 6 | 8 |
Number (count) of participants that experienced at least 1 adverse event.
| Participants | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Incidence of Adverse Events | 29 | 22 | 11 | 11 | 12 |
Number (count) of participants that experienced a Grade 3 or higher maximum post-baseline laboratory toxicity (hematology and chemistry). Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), v4.03. Grade 1 = mild, no intervention needed; Grade 2 = moderate, minimal intervention needed; Grade 3 = severe or medically significant, hospitalization is required; Grade 4 = life-threatening, urgent intervention needed; Grade 5 = death related to adverse event.
| Participants | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Any Hematology Test | 10 | 16 | 4 | 6 | 4 |
| Lymphocytes (x10^3/uL) | 8 | 15 | 3 | 4 | 4 |
| Absolute Neutrophil Count (x10^3/uL) | 4 | 4 | 1 | 2 | 0 |
| Neutrophils (x10^3/uL) | 4 | 4 | 1 | 2 | 0 |
| Leukocytes (x10^3/uL) | 3 | 2 | 1 | 1 | 1 |
| Hemoglobin (x10^3/uL) | 0 | 1 | 0 | 1 | 0 |
| Platelets (x10^3/uL) | 1 | 1 | 0 | 0 | 0 |
| Any Chemistry Test | 4 | 7 | 2 | 1 | 3 |
| Glucose (mg/dL) | 3 | 5 | 0 | 0 | 1 |
| Potassium (mEq)/L | 0 | 2 | 1 | 1 | 2 |
| Calcium (mg/dL) | 1 | 1 | 0 | 0 | 0 |
| Sodium (mEq/L) | 0 | 2 | 0 | 0 | 0 |
| Alanine Aminotransferase (IU/L) | 0 | 0 | 1 | 0 | 0 |
Number (count) of participants that achieved complete or partial remission at the end of treatment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007)
| Participants | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Objective Response Rate | 23 | 19 | 10 | 10 | 9 |
Median progression-free survival (in months) and observed minimum-maximum range.
| Months | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Progression-free Survival | NA (0.62 to 40.21) | NA (1.28 to 39.85) | NA (3.35 to 24.34) | NA (3.25 to 15.41) | NA (1.25 to 16.43) |
Median overall survival (in months) and observed minimum-maximum range.
| Months | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Overall Survival | NA (0.62 to 42.79) | NA (1.28 to 44.29) | NA (16.56 to 25.76) | NA (3.25 to 16.85) | NA (1.25 to 19.22) |
Collected over Adverse events were reported from study Day 1 (predose) though the EOT visit or 30 days after the last study treatment (Brentuximab vedotin or combination treatment), whichever was later. However, all protocol-related AEs were collected from the time of informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: BV(1.2 mg/kg) + RCHOP | 1/29 (3.4%) | 16/29 (55.2%) | 29/29 (100%) |
| Part 1: BV(1.8 mg/kg) + RCHOP | 2/22 (9.1%) | 14/22 (63.6%) | 22/22 (100%) |
| Part 2: BV(1.8 mg/kg) + RCHP | 0/11 (0%) | 5/11 (45.5%) | 11/11 (100%) |
| Part 3: BV(1.8 mg/kg) + RCHP | 1/11 (9.1%) | 4/11 (36.4%) | 11/11 (100%) |
| Part 3: RCHOP | 2/12 (16.7%) | 4/12 (33.3%) | 12/12 (100%) |
| Event | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 8/29 | 8/22 | 2/11 | 0/11 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 0/29 | 0/22 | 0/11 | 2/11 | 0/12 |
| PancytopeniaBlood and lymphatic system disorders | 1/29 | 0/22 | 0/11 | 1/11 | 0/12 |
| BacteraemiaInfections and infestations | 2/29 | 0/22 | 1/11 | 0/11 | 0/12 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/29 | 0/22 | 1/11 | 0/11 | 0/12 |
| PneumoniaInfections and infestations | 1/29 | 2/22 | 0/11 | 0/11 | 0/12 |
| Escherichia sepsisInfections and infestations | 0/29 | 0/22 | 0/11 | 1/11 | 0/12 |
| NauseaGastrointestinal disorders | 0/29 | 0/22 | 1/11 | 1/11 | 0/12 |
| VomitingGastrointestinal disorders | 0/29 | 0/22 | 1/11 | 1/11 | 0/12 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/29 | 0/22 | 0/11 | 1/11 | 0/12 |
| Event | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 14/29 | 15/22 | 8/11 | 4/11 | 2/12 |
| AlopeciaSkin and subcutaneous tissue disorders | 5/29 | 9/22 | 8/11 | 3/11 | 3/12 |
| FatigueGeneral disorders | 17/29 | 16/22 | 7/11 | 2/11 | 3/12 |
| DiarrhoeaGastrointestinal disorders | 14/29 | 15/22 | 3/11 | 6/11 | 1/12 |
| Peripheral sensory neuropathyNervous system disorders | 16/29 | 15/22 | 6/11 | 4/11 | 4/12 |
| VomitingGastrointestinal disorders | 7/29 | 14/22 | 2/11 | 2/11 | 0/12 |
| ConstipationGastrointestinal disorders | 8/29 | 9/22 | 6/11 | 1/11 | 5/12 |
| Decreased appetiteMetabolism and nutrition disorders | 7/29 | 10/22 | 2/11 | 2/11 | 3/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/29 | 9/22 | 0/11 | 3/11 | 4/12 |
| DehydrationMetabolism and nutrition disorders | 3/29 | 9/22 | 2/11 | 2/11 | 1/12 |
| Age, Categorical(Participants) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 11 | 7 | 5 | 6 | 39 |
| >=65 years | 19 | 11 | 4 | 6 | 6 | 46 |
| Age, Continuous(years) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| Median | 70 (33 to 80) | 64 (21 to 81) | 59 (22 to 78) | 68 (46 to 74) | 65 (41 to 80) | 66 (21 to 81) |
| Sex: Female, Male(Participants) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| Female | 13 | 6 | 4 | 10 | 6 | 39 |
| Male | 16 | 16 | 7 | 1 | 6 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 1 | 0 | 1 | 8 |
| Not Hispanic or Latino | 25 | 18 | 8 | 11 | 11 | 73 |
| Unknown or Not Reported | 0 | 2 | 2 | 0 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 1 | 0 | 4 |
| White | 27 | 17 | 8 | 10 | 12 | 74 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 1 | 0 | 0 | 5 |
| Region of Enrollment(participants) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| United States | 29 | 22 | 11 | 8 | 10 | 82 |
| Czechia | 0 | 0 | 0 | 1 | 1 | 2 |
| Poland | 0 | 0 | 0 | 2 | 0 | 2 |
| Italy | 0 | 0 | 0 | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Part 1: BV(1.2 mg/kg) + RCHOP | Part 1: BV(1.8 mg/kg) + RCHOP | Part 2: BV(1.8 mg/kg) + RCHP | Part 3: BV(1.8 mg/kg) + RCHP | Part 3: RCHOP | Total |
|---|---|---|---|---|---|---|
| 0 | 5 | 4 | 1 | 4 | 4 | 18 |
| 1 | 16 | 12 | 4 | 4 | 3 | 39 |
| 2 | 8 | 6 | 6 | 3 | 5 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Aug 2013, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Vincristine
Lymphoma, Large B-Cell, Diffuse →